Triaziquone

Triaziquone is an aziridinylbenzoquinone-based alkylating agent that was used as a chemotherapeutic drug. It acts by forming intrastrand crosslinks with DNA through its alkylating groups, thereby inhibiting DNA and RNA synthesis and leading to cytotoxic effects in cancer cells. Triaziquone was clinically used intravenously during the 1960s for the treatment of various cancers including leukemias (such as chronic lymphocytic leukemia), lymphomas (including Hodgkin's disease), ovarian cancer, and topically for basal cell skin cancers. Its antitumor activity is attributed to both direct DNA/protein alkylation and induction of oxidative stress. Due to significant toxicity—particularly bone marrow suppression and vascular toxicity—it has been replaced by more effective agents and is no longer in clinical use[1][3][4][5].

Other names

triazicuona2,3,5-Tris(aziridin-1-yl)cyclohexa-2,5-diene-1,4-dione